- Driven by Evidence
Medical Affairs Solutions
Medical Affairs Solutions That Turn Clinical Evidence Into Market Credibility
- Medical Affairs: Proof, Not Just Promise
Medical Affairs Solutions That Earn Real Trust.
In value-based healthcare, prescribers and payers do not take commercial claims at face value. They take evidence. OneAlphaMed is the medical affairs agency that builds it from RWE study design and strategic publication planning to MERLIN AI-powered medical information services and Tier-1 academic CME programs. Our pharmaceutical medical affairs model has certified 15,000+ HCPs, runs compliant medical information 24/7 across 25 countries, and is trusted by Pfizer, GSK, Abbott, Bayer, Cipla, and Dr. Reddy’s to protect and grow brand credibility at every stage of the product lifecycle.
15K+
HCPs Certified
90%+
Relevance Score
100%
Brand-Safe Awareness
30+
Pharmaceutical Companies
Why Choose OneAlphaMed as Your Medical Affairs Partner
Most medical affairs consulting firms handle one dimension – publication planning, or KOL engagement, or compliance. We connect all of them, and we bring proprietary technology
the rest of the market cannot.
MERLIN AI - Proprietary Pharma-Specific Medical Information Engine.
Our RAG-based AI model, MERLIN, answers HCP and patient medical information queries using only verified sources – PubMed, peer-reviewed journals, and authorised internal databases. Air-gapped security architecture means no query
data touches public AI models. Every response is audit-trailed and fully within your compliance framework. No other medical affairs agency in India offers this.
Tier-1 Academic Partnerships - Neutral, Credible, Certifiable.
We build CME and CPD programs in partnership with Tier-1 academic hospitals and institutions – including the Association of Otolaryngologists of India (AOI) – so your
medical education carries independent scientific authority, not just brand endorsement. 15,000+ HCPs certified. >90% relevance scores. 100% brand-safe.
One Team. Strategy, Science, Compliance, and AI.
Medical affairs outsourcing with OneAlphaMed means brand strategy, medical communications, regulatory compliance, and AI-powered HCP digital tools are built
by one aligned team under one brief — not three separate vendors. Your scientific narrative stays consistent from publication planning to the prescriber’s inbox.
Our Medical Affairs & Scientific Communications Services
Nine integrated medical affairs capabilities – from pre-launch evidence generation through post-approval lifecycle management – delivered by one scientific and commercial team.
Payers and HTA bodies do not approve formulary access on Phase 3 data alone. They ask what happens in the real world -to real patients, under real prescribing conditions.
- We design observational studies and patient registries that capture long-term safety signals and treatment outcomes in routine clinical settings – answering the questions that randomised trials were never designed to address.
- Our dual-evidence strategy combines Real-World Data (RWD) with clinical trial findings to give payers, HTA bodies, and formulary committees the comparative evidence they require.
- RWE protocol writing, claims data analytics, and non-interventional study management are fully handled by our scientific affairs team, from protocol development through to manuscript publication.
A clinical dataset that does not get published is a missed opportunity. A publication plan without strategic sequencing and optimal communications service is a wasted one.
- We build multi-year publication plans that construct your brand’s scientific evidence base milestone by milestone – from Phase 3 readouts through post-marketing surveillance and RWE studies.
-
Our medical writing team handles manuscript authorship, journal targeting, and peer review
navigation – so your clinical findings reach the prescribers and payers who matter most with the
weight of the right journal behind them, not just a placement that cleared the submission process. - ICMJE authorship standards, GPP4 guidelines, and global transparency disclosure requirements are not compliance boxes we check at the end. They are the framework the publication is built inside because scientific credibility, once lost on an authorship or disclosure issue, is very hard to rebuild.
- Visual abstracts, plain language summaries, and omnichannel content distribution pull publication reach beyond the journal – onto the digital medical channels, congress platforms, and HCP feeds where your target prescribers actually spend their time.
Advisory boards that feel like listening exercises produce generic feedback. Boards with a structured scientific mandate produce intelligence that changes strategy.
- We structure KOL advisory boards that give your top clinical experts a meaningful role in medical strategy – shaping label refinement, trial design direction, and lifecycle evidence planning.
- KOLverse gives you immediate access to 500+ verified experts across 35 countries spanning Cardiology, Oncology, Respiratory, Endocrinology, and Neurology. No procurement cycle, no cold outreach, no waiting six months to identify the right room of people.
- Asynchronous advisory board formats give experts time to sit with the data before they respond to it. That changes the quality of what comes back – considered scientific input rather than the positions people default to when a room is watching them in real time.
-
Every session closes with structured strategic intelligence your medical affairs team can act on
directly – mapped to publication planning, next-cycle evidence generation, or lifecycle decisions, not left as meeting notes in a slide deck nobody reopens.
A congress symposium without a clear scientific agenda is brand noise. One built around the right clinical data, the right faculty, and the right follow-through becomes a defining moment for your therapy area.
- We plan and execute symposia that position your brand as the leading scientific voice in its therapy area – at international congresses and as standalone medical education events.
-
Abstract strategy, faculty coordination, and presentation development
are managed by our
team so your scientific leadership shows up consistently on the day – not just in the programme book. - AR/VR scientific posters and immersive data visualisations make complex mechanisms of action and clinical data immediately accessible to prescribers at congresses.
- Post-symposium content strategy extends scientific momentum through digital medical channels and peer-reviewed publications in the weeks after the event.
Prescribing habits form early and change slowly. Medical education that reaches the right doctors at the right stage of their career is one of the highest-return investments in pharmaceutical medical affairs.
- We develop accredited CME and CPD programmes across live webinars, in-clinic modules, and digital learning pathways – reaching over 15,000 enrolled HCPs through Tier-1 academic partnerships.
- Clinical case simulations with branching-logic patient scenarios sharpen diagnostic accuracy and give prescribers the evidence-based confidence to act earlier in the patient journey.
- We take post-graduate education to Tier-2 and Tier-3 cities where brand advocacy forms at the exact moment young doctors develop their clinical patterns – reaching the prescribers of the next decade.
- Academic partnerships with institutions including the AOI give programmes independent institutional authority that branded medical education alone cannot achieve.
The prescribers who will define your brand's market position in five years are in residency right now. Post-graduate education is where long-term brand advocacy is built.
- We design education programmes for residents and post-graduate fellows at the stage where clinical patterns take root and prescribing preferences form – before the competition gets there.
- Modular, evidence-based content runs through our Next-Gen LMS and scales from a single hospital to a national multi-specialty rollout without losing scientific quality or compliance integrity.
- Partnerships with medical associations give programmes accredited institutional reach across India’s teaching hospital network – extending your brand’s scientific influence into the next generation of prescribers.
A single non-compliant asset can undo years of carefully built medical credibility. Medical regulatory compliance is not a review step - it is a medical affairs management discipline.
- We audit all medical communications assets against FDA OPDP, EFPIA, and UCPMP standards across every market your brand operates in promotional and non-promotional channels alike.
- AI-driven MLR review uses NLP to pre-screen promotional materials and reduce review cycle time catching compliance issues before they reach the regulatory team
- Compliance training programmes give medical affairs and commercial teams clear, practical SOPs for HCP engagement, congress activity, and digital content across all markets.
- IRB submissions, ethics board navigation, and transparency disclosure reporting for investigator-sponsored studies are fully managed by our regulatory affairs team.
HCPs and patients expect accurate, rapid responses to medical queries. An overloaded, under-resourced MedInfo function is a compliance risk and a brand credibility risk simultaneously.
- MERLIN – our proprietary RAG-based pharma AI – answers HCP and patient medical information queries using only verified sources from PubMed, peer-reviewed journals, and authorised internal databases. No hallucinations. No public AI exposure.
- Air-gapped security architecture and mandatory audit trails mean no query data touches external AI models, and every response is fully within your compliance and pharmacovigilance framework – 24/7.
- Standard Response Letter (SRL) libraries and FAQ databases are continuously updated through vigilant literature monitoring so your MedInfo function stays current with the evolving evidence base.
- Omnichannel MedInfo deployment across phone, email, and digital channels ensures HCP queries are answered at the point of need – not after a five-day turnaround.
Formulary access decisions are not made on clinical efficacy alone. Payers and HTA bodies need a compelling economic case and they need it in their language, not yours.
- We build HEOR packages including budget impact models, cost-effectiveness analyses, and quality-of-life data that give formulary committees the financial evidence they require for drug adoption decisions.
- Patient-Reported Outcome (PRO) studies and indirect treatment comparisons give Health Technology Assessment bodies the comparative evidence they need – especially for first-in-class or premium-priced therapies.
- Global Value Dossiers aggregate clinical, economic, and humanistic evidence into one definitive source of truth for payer submissions across India, Southeast Asia, and European markets.
- HEOR findings are translated into payer-facing value narratives written specifically for formulary committees – not adapted from clinical manuscripts.
Medical Affairs Outsourcing & Consulting for Every Stage of Your Brand
Whether you need a full medical affairs function built from the ground up, or targeted scientific communications support for a specific evidence gap — OneAlphaMed structures engagements around your needs.
Full Medical Affairs Outsourcing
For pharmaceutical companies entering new markets, launching new assets, or building a medical function without an in-house team. We act as your complete embedded medical affairs department – covering evidence generation, publication planning, KOL engagement, medical information, and regulatory compliance.
Medical Affairs Consulting & Strategy
For established Medical Affairs teams that need external scientific strategy, publication planning, or KOL advisory expertise for a specific asset or lifecycle event. We work alongside your team as a strategic extension – not a replacement.
Scientific Communications Agency Services
Medical writing, publication planning, CME/CPD development, and omnichannel scientific content for brands that need high-quality medical communications without full outsourcing. Delivered to ICMJE, GPP4, and UCPMP standards.
Specialist Pharma & Biotech Medical Affairs Support
First-in-class, rare disease, and specialty pharma launches require deeper KOL networks, more rigorous evidence plans, and more precise HEOR packages than standard medical affairs models deliver. OneAlphaMed’s specialist therapy area experience covers Oncology, Rare Disease, Cardiology, Respiratory, CNS, and Endocrinology.
- Common Questions
Frequently Asked Questions About Our Medical Affairs Services
OneAlphaMed provides a full spectrum of medical affairs solutions - including Real-World Evidence study
design, strategic publication planning, KOL advisory boards, accredited CME/CPD programmes, scientific
symposia management, regulatory and ethics compliance, MERLIN AI-powered medical information
services, and Health Economics & Outcomes Research (HEOR). All services are delivered by one integrated
scientific and commercial team - not outsourced to subcontractors.
Three proprietary assets set us apart from other medical affairs agencies. MERLIN AI - our RAG-based
pharma language model delivers 24/7 compliant medical information using only verified sources, with
air-gapped security architecture. KOLverse gives clients instant access to 5,000+ verified KOLs across 35
countries. And our Tier-1 academic hospital partnerships mean CME programmes carry independent
scientific authority - not just commercial sponsorship. We have deployed these capabilities for Pfizer, GSK,
Abbott, Bayer, Cipla, Dr. Reddy's, and 20+ other pharmaceutical leaders.
Yes and it is one of our most frequent engagement models. For pharmaceutical companies entering the
Indian market, we build the complete medical affairs infrastructure: RWE studies aligned to Indian patient
data, DCGI-compliant medical communications, CME programmes through Tier-2 and Tier-3 city medical
associations, and UCPMP-compliant KOL engagement frameworks. We act as your full embedded medical
affairs department until you are ready to build in-house.
Regulatory compliance is embedded at the point of content creation not applied as a review layer at the
end. Our AI-driven MLR review system uses NLP to pre-screen all promotional and non-promotional
materials against FDA OPDP, EFPIA, and UCPMP standards before they reach the formal review cycle. Our
regulatory team manages IRB submissions, ethics board navigation, and transparency disclosure reporting
for investigator-sponsored studies across every market we operate in.
Most RWE programmes are commissioned after payers ask for them. We build RWE evidence plans at
Phase 3 - identifying the questions payers and HTA bodies will ask and designing the observational studies
and patient registries to answer them before formulary access negotiations begin. Our dual-evidence
strategy combines Real-World Data with clinical trial findings, and our scientific writing team manages the
full pathway from protocol design to peer-reviewed publication.
We can begin a scoping engagement within five business days. For active medical affairs outsourcing or
consulting retainers, we typically onboard within two to three weeks - covering a medical affairs audit,
publication gap analysis, KOL landscape mapping, and initial evidence strategy workshop. Contact our
team to discuss your asset, therapy area, and current medical affairs maturity.
The OneAlphaMed Approach
Evidence-Based Medical Communication: We take real-world evidence, clinical data, and clinic-floor conversations and turn them into credible medical communication that healthcare professionals actually use in prescribing and patient management.
- Let's Talk
Connect with a Strategic Advisor
Reach out for appointments, strategic discussions, or partnership enquiries.
We get back quickly and point you to exactly the right solution.